- The purchase-order line, supplier product code, manufacturing lot, COA and container label must identify the same material and quantity basis.
- A COA reports selected release tests; it does not replace the underlying batch history, change records or shipping evidence.
- Treat a split or repacked lot as a documented parent-child relationship, not a new unexplained number.
- Investigate mismatches before accepting the shipment; a plausible product name is insufficient.
What does peptide batch traceability actually prove?
Batch traceability is the ability to connect the material received by a buyer to its defined manufacturing and testing history. Start with a unique lot identifier, then follow it through synthesis or sourcing, purification, drying, packaging, release and dispatch. For a listed PeptideSum product, the public catalog ID and COA SKU help identify the requested item; neither should be confused with the actual manufacturing lot on a shipment. The lot-specific COA, container label and packing list must resolve to the same released material.
ICH Q7 describes identification and status control for incoming material, batch production records, laboratory records and distribution records in its API scope [1]. Those provisions are a useful benchmark for a buyer's questions, but they do not make every research or cosmetic peptide an API or certify a supplier as GMP-compliant. Ask the supplier which quality system applies to the exact product and site.
- Product identity: name, sequence or agreed identity, catalog ID and COA SKU
- Lot identity: manufacturing lot, release status and any repack or sublot link
- Commercial identity: ordered pack, number of containers and destination
Which documents should agree before a bulk order is released?
Compare the purchase order, approved specification, lot-specific COA, label artwork or sample label, packing list and invoice as one set. The COA should state tests, methods or method references, limits and actual results. The label should identify the supplied form and lot without implying a different grade or use. The packing list should reconcile container count and net quantity; shipment documents should preserve the link after the material leaves the facility.
A generic example COA can help a buyer understand the format but cannot release a commercial lot. Equally, an HPLC chromatogram without the sample identifier and method context cannot be reliably linked to the container. ICH Q7 calls for COA information such as product name, batch number, test results and authorized quality-unit signature in its applicable scope [1]. Use that principle to specify the evidence needed for your own risk level.
The five-field reconciliation
Read across documents in this order: product or sequence; lot or sublot; pack size and container count; release date or status; and applicable destination or shipping reference. If one field differs, request a written reconciliation before receipt acceptance.
- PO and approved specification
- Lot-specific COA and supporting traces where agreed
- Container label and packing list
- Invoice, dispatch reference and shipment conditions
How should repacking, split lots and changes be handled?
A wholesale lot may be divided into several pack sizes or shipments. That is manageable if the repack identifier points back to the parent lot and the amount issued can be reconciled with the amount originally released. Record who performed the repack, when it happened, the container and closure used, and whether the operation introduced a new stability or contamination risk. The original analytical result remains meaningful only when the link and subsequent controls are credible.
A change in synthesis site, raw-material source, purification method, counter-ion, primary pack or test method can alter the meaning of a repeat order even when the product name stays the same. Buyers should define which changes require notice, comparability data or a new sample. ICH Q7 treats changes as controlled records rather than silent substitutions [1]. The exact notification arrangement is a commercial quality agreement decision, not a universal default.
- Record parent and child lot numbers
- Reconcile quantities and container count
- Log packaging and release decisions
- Define material change-notification triggers
What should the buyer check at receipt?
At receipt, inspect outer packaging for damage or tampering and check the container labels against the order and packing list before treating the material as accepted. Record the arrival date, condition, quantity and any temperature-monitoring evidence required by the agreed shipping plan. Place an unexplained mismatch or excursion on hold while the supplier supplies a deviation assessment. The release decision should be traceable to named documents and an authorized person.
Do not infer product integrity from an intact carton alone. Peptide stability depends on the sequence, moisture, salt form, supplied state and packaging, so a transport excursion requires product-specific evidence rather than a generic assurance. ICH Q1A(R2) distinguishes release specifications from stability over time [2]; apply that distinction when deciding whether a pre-dispatch COA answers a post-transport question.
- Inspect seals and label-to-document match
- Record quantity and arrival condition
- Review agreed shipping conditions and deviations
- Document acceptance, hold or rejection
This article is for laboratory, analytical, procurement and qualified cosmetic-science contexts. It is not medical advice and does not provide dosing, administration or personal-use instructions.
Frequently asked questions
Is a peptide COA the same as a batch record?+
No. A COA summarizes specified test results for an identified lot. A batch record documents manufacturing and control steps. Ask for an appropriate audit trail or quality summary when procurement risk requires more than the COA.
Can one COA cover different vial pack sizes?+
It may cover containers derived from the same released lot if the supplier documents the split, quantities and packaging controls. The pack labels and invoice must retain the parent-lot link; do not assume matching product names prove it.
What if the vial label and COA lot numbers differ?+
Hold acceptance and request the supplier's written lot reconciliation. A documented repack or sublot can explain a difference; an unexplained mismatch cannot be treated as a clerical detail.
Does ICH Q7 automatically apply to every peptide listing?+
No. ICH Q7 is guidance for active pharmaceutical ingredients. It is cited here as a quality-record reference. The buyer must verify the applicable quality and regulatory scope for the specific material.